ssd8432
Small moleculeexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Apr 7, 2022 (NCT05339646)
Timeline
Indications
Mechanism of action
- Replicase polyprotein 1aINHIBITOR
Replicase polyprotein 1a inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05373433 | Phase 2/Phase 3 (Phase 3) | May 26, 2022 | Simcere Pharmaceutical Co., Ltd, Xiansheng Pharmaceutical Company |
| NCT05373446 | Phase 2 | May 20, 2022 | Simcere Pharmaceutical Co., Ltd, Xiansheng Pharmaceutical Company |
| NCT05369676 | Phase 1/Phase 2 (Phase 2) | May 14, 2022 | Simcere Pharmaceutical Co., Ltd, Xiansheng Pharmaceutical Company |
| NCT05339646 | Phase 1 | Apr 7, 2022 | Simcere Pharmaceutical Co., Ltd |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Simcere Pharmaceutical Co., Ltd | For profit | 4 | 4 | 3 | 2022 |
| Xiansheng Pharmaceutical Company | For profit | 3 | 0 | 2 | 2022 |
2 organizations
Page 1 / 1